EGFR and central nervous system cancer: In the past decades, molecular targeted therapies are beneficial to improve the prognosis of gliomas, such as bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF) [9], nimotuzumab, a monoclonal antibody to epidermal growth factor receptor (EGFR) [10] and several patients of gliomas with silencing of O6-methylguanine DNA methyltransferase (MGMT) could aggrieve more benefits from temozolomide (TMZ) [11].